CAMBRIDGE, Mass.–(BUSINESS WIRE)–MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in-licensing of a next-generation selective PARP1 (poly ADP-ribose polymerase) inhibitor, now known as MOMA-989. The company also provided an update on the clinical progress of Polθ inhibitor MOMA-313 and outlined the clinical path for Werner inhibitor MOMA-341. “The addition of this selective PARP1 inhibitor

BURLINGTON, Mass & NEW YORK–(BUSINESS WIRE)—- $BFLY #POCUS–Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”, “the Company”), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced that it expects to report revenue growth for the fourth quarter ended December 31, 2024 of approximately 35% year over year. Joseph DeVivo, Butterfly’s President, Chief Executive Officer and Chairman commented, “The Butterfly team closed out 2024

BILLERICA, Mass.–(BUSINESS WIRE)—- $BRKR #BRKR–Bruker Corporation (Nasdaq: BRKR) today announced the launch of the LUMOS™ II ILIM, a quantum cascade laser (QCL) based infrared imaging microscope. The new LUMOS II ILIM redefines performance standards, enabling pharma and life science researchers to capture ultrafast IR images of expansive areas with enhanced spatial resolution. The LUMOS II ILIM features a patented coherence reduction method for infrared laser imaging essentially free from artifacts in both

TUTTLINGEN, Germany–(BUSINESS WIRE)–The family-owned MedTech company KARL STORZ is pleased to announce the acquisition of the medical business of T1V, a US-based visual collaboration software company. KARL STORZ has had a longstanding partnership with T1V to build its existing CollaboratOR portfolio. This acquisition marks a significant step for KARL STORZ in shaping integrated hardware and software solutions for digital surgery in global operating rooms, complementing its state-of-the-art en

DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer’s, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial me

BOSTON–(BUSINESS WIRE)–PureTech to present at 43rd annual J.P. Morgan Healthcare Conference.

RAHWAY, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck’s GARDASIL® Receives Expanded Approval for Males in China

ATLANTA–(BUSINESS WIRE)–UPS (NYSE: UPS) today announced that it has completed the acquisition of Frigo-Trans and its sister company BPL, which provide industry-leading, complex healthcare logistics solutions across Europe. The acquisitions further enhance the end-to-end capabilities available to UPS Healthcare customers, who increasingly need temperature-controlled and time-critical logistics solutions globally. Frigo-Trans’ network includes temperature-controlled warehousing ranging from cry

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics, Inc. (NASDAQ: SAGE) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 8:15 a.m. PT in San Francisco, CA. A live webcast of the presentation can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutic

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 61,000 shares of KalVista common stock on January 2, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock